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Conclusions: Further research is warranted to deﬁne the role of theT-
GFBR1 Int7G24A gene in customized treatments.
 N OR (95% CI) P
ARM 
Control 126 0.57 (0.34-0.93) 0.02
Low ERCC1 114 1 ref  
High ERCC1 84 0.80 (0.46-1.39) 0.54
PS 
o 124 1 ref  
1 200 0.55 (0.35-0.85) 0.004
XRCC3 
ThrThr 138 0.82 (0.51-1.32) 0.42
ThrMet 155 1 ref  
MetMet 31  0.30 (0.12-0.72) 0.007
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Plasma lactate dehydrogenase (LDH) is a biochemical parameter sup-
posed to get elevated in lung cancer, especially in advanced tumors. 
LDH is an important enzyme which catalyses lactate formation from 
pyruvate in anaerobic metabolism. It is called to be a non-speciﬁc 
indicator of dying tumor cells by reﬂecting their rapid turnover. In our 
study, we aimed to show that plasma LDH levels are found to be high 
in lung cancer and LDH can reﬂect the stage and prognosis of tumor. 
We detected 40 patients with new diagnosis of non small cell lung 
cancer. We chose a control group of 40 patients with chronic obstruc-
tive pulmonary disease (COPD). In lung cancer group, we chose the 
patients without history of COPD; also COPD patients elected for con-
trol group didn’t have diagnosis of lung cancer. The history of smoking 
wasn’t thought to affect the results of our study as it was an intersection 
of both groups. Gender and age were found to be statistically similar 
for each group. We accepted the normal plasma level of LDH between 
240-480 U / l.
The mean level of LDH was 606,5 U / l in lung cancer group when it 
was found as 387,3 U / l in control group which was statistically sig-
niﬁcant (p=0,002). In control group, we found 7 patients having a high 
value of LDH (15 %); it seemed to be high in 20 patients of lung cancer 
group (%50).
Afterwards, NSCLC group was examined if LDH levels differed ac-
cording to stage and tumoral type. By using TNM staging, 26 of 40 
patients were found to be in stage IV, 7 in stage IIIb and 7 in stage 
IIIa. Plasma level of LDH was high in 14 of 26 stage IV patients, 3 in 
7 stage IIIb and 3 in 7 stage IIIa. We examined mean LDH levels ac-
cording to stages of tumors: 453.8 in stage IIIa, 508.3 in stage IIIb, and 
684.2 in stage IV, which shows that LDH is high in advanced NSCLC. 
However, LDH levels weren’t found statistically signiﬁcant according 
to stages. We think that the heterogen distribution of tumor stages can 
be the reason of it.
There were 15 squamous cell, 15 adenocarcinoma and 10 uncertain 
histopathological type of NSCLC in lung cancer group. LDH was high 
in 6 of 15 squamous cell, in 8 of 15 adenocarcinoma and in 6 of other 
10 NSCLC. The mean LDH level was 504.1 in squamous cell, 642.5 in 
adenocarcinoma and 673 in other NSCLC; we can see that LDH levels 
are higher in adenocarcinoma. This data achieved according to tumor 
types wasn’t found statistically signiﬁcant; the limited number of the 
universe can explain this result.
The results of our study supports that plasma LDH levels are higher 
in patients with lung cancer. Although LDH levels were found to be 
high in advanced NSCLC and in adenocarcinoma,but statistically not 
signiﬁcant, more advanced studies with a high number and homogen 
distribution of patients should have done to conﬁrm these results. 
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Background: There are some data supporting differences by sex 
in lung cancer. So we undertook a retrospective analysis of clinico-
pathologic and genetic features in women (W) with advanced NSCLC 
participating in ﬁrst-line chemotherapy (CT) SLCG trials. 
Methods: Data on age, histology, PS, CT schedule, XRCC3 (DNA 
repair capacity gene) single nucleotide polymorphisms (SNPs) as-
sessment in DNA from peripheral blood lymphocytes, CT outcomes, 
survival and disease free-survival were obtained. 
Results: 1125 p included in 4 SLCG trials from 2001 to 2005 treated 
with CT based on CDDP/GEM, CDDP/DOC or DOC/GEM were 
analysed. 167 p (14.9%) were W. W were signiﬁcantly younger than 
men (M) (median, 57 yrs vs 61 yrs, P<0.0001). Adenocarcinoma 
subtype was more predominant in W than in men (76% vs 47%, 
P<0.0001). There were not signiﬁcant differences by sex considering 
PS (0/1)(P<0.85), stage (IIIB/IV)(P<0.18) or overall response rate 
(P<0.45). Median time to progression (TTP) was 6.8 months (m) vs 5.3 
m (P<0.009) in favour of W. Median overall survival (OS) was 11.4 
m for W vs 9.1 m for M (P<0.001). No differences were found in the 
subgroup of patients receiving DOC/GEM probably due to the small 
number of patients. XRCC3 SNPs were distributed similarly between 
sexes. SNPs genotype of both XRCC3 241Met/Met and Thr/Met 
correlates with better survival in W vs M (P<0.05 and P<0.008). In a 
multivariate analysis, sex was an independent predictive marker for 
both OS (HR 1.5, 95% CI 1.2-1.9, P<0.0001) and TTP (HR 1.4, 95% 
CI 1.1-1.7, P<0.001), others independent variables found were PS, age, 
type of CT, but not XRCC3 241 genotype.
Conclusions: In this retrospective analysis of four SLCG trials, women 
with NSCLC were found to have better prognosis than men. Results 
